Product
Taxotere
Aliases
docetaxel, Taxotere (docetaxel)
Name
Docetaxel
INN Name
docetaxel
FDA Approved
Yes
6 clinical trials
19 organizations
10 indications
2 documents
Indication
Breast CancerIndication
Stomach CancerIndication
Stomach AdenocarcinomaIndication
Gastroesophageal Junction AdenocarcinomaIndication
Triple-Negative Breast CancerIndication
Esophageal cancerIndication
Esophageal CancerIndication
Esophageal NeoplasmIndication
NSCLCIndication
Gastric CancerClinical trial
Open-label, Randomized, Active-controlled, Multicenter, Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant Chemotherapy in Patients With Breast CancerStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Multicenter, Randomized, Controlled Phase III Clinical Study of Docetaxel for Injection (Albumin-bound) Versus Taxotere in Gastric CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
An Open-label, Randomized, Positive Drug-controlled Phase Ⅱ Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Global, Multicenter, Three Arms, Open-label Randomized Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere® (Docetaxel Injection Concentrate) in Triple-negative Breast Cancer Patients With Locally Advanced or Metastatic Breast Cancer After Failure to Prior ChemotherapyStatus: Recruiting, Estimated PCD: 2024-05-31
Clinical trial
A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
A Phase II Study of Irinotecan and Taxotere With Concurrent Radiotherapy as a Preoperative Treatment in Resectable Esophageal CancerStatus: Completed
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Document
DailyMed Label: DocetaxelOrganization
Dr. Reddy's Laboratories Inc.Organization
Actavis Pharma, Inc.Organization
Mylan Institutional LLCOrganization
Sagent PharmaceuticalsOrganization
Hospira, Inc.Organization
Hikma Pharmaceuticals USA Inc.Organization
Sandoz Inc. Organization
Gland Pharma LimitedDocument
DailyMed Label: DOCIVYXOrganization
Avyxa Pharma, LLCOrganization
Alembic Pharmaceuticals LimitedOrganization
Amneal Pharmaceuticals LLCOrganization
Alembic Pharmaceuticals Inc.Organization
Xiromed LLCOrganization
Accord Healthcare Inc.Organization
AuroMedics Pharma LLCOrganization
Ingenus Pharmaceuticals, LLCOrganization
Baxter Healthcare Corporation